We also highlight alternative cell cycle targets, such as CDK2 and CDK7, as well as novel combination trials that remain under investigation, in which CDK4/6 is used to modulate the biology of the prostate cancer cell rather than effect a cytostatic change. This evidence concerns the gene CDK2 and prostate carcinoma.